Figure 4 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer

Auranofin synergizes with cisplatin to reduce tumor burden in an OVCAR3 CDX mouse model. A, Weekly in vivo imaging system spectrum in vivo bioluminescent images showing tumor burden in OVCAR3 CDX mice treated with placebo, cisplatin, auranofin, or both drugs, according to the regimen shown. B, Tumor growth over time shown as mean normalized bioluminescence ± SEM for each treatment group (n = 5 mice per group at baseline). C, Raw P values plotted over time comparing cisplatin monotherapy with auranofin–cisplatin combination treatment. Statistical significance (red dots) was determined using multiple unpaired t tests. D, Tumor burden of individual mice at the end of two treatment cycles (week 7). Unpaired t tests were used for statistical comparison. *, P < 0.05; **, P < 0.01; ***, P < 0.001. E, AUC analysis of normalized tumor burden over time (weeks 3–13) shown as box and whisker plots. Both tumor growth and shrinkage phases were quantified. Statistical comparisons were performed using one-way ANOVA with Holm–Šídák multiple comparisons. F, Kaplan–Meier survival curves. Statistical significance was determined with unpaired t tests. *, P < 0.05; ***, P < 0.001.